ConjuChem Company
ConjuChem creates novel, next-generation medicines using unique, long-acting therapeutic peptides. Underlying all ConjuChem compounds are bioconjugation platforms called Drug Affinity Complex (DAC™) and Preformed Conjugate-Drug Affinity Complex (PC-DAC™). When applied to a given peptide, DAC™ and PC- DAC™ can create new drugs with similar therapeutic activities but with significantly longer durations of activity and improved safety profiles.
Founded Date:
1997
Estimated Revenue:
Less than $1M
Employee Number:
11-50
Industry:
Metabolism Dysfunctions
Technology:
Metabolic Disorders
Headquarters:
United States